Symbiomix Therapeutics LLC

NEW YORK, Nov. 1, 2022 /PRNewswire/ -- Abstract: What’s New for 2022? Global competitiveness and key competitor percentage market shares Read the full report: Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Global Vaginitis Therapeutics Market to Reach $5.2 Billion by 2027 In the changed post COVID-19 business landscape, the global market for Vaginitis Therapeutics estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 8% over the analysis period 2020-2027. Anti-Bacterial, one of the segments analyzed in the report, is projected to record a 7.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Anti-Fungal segment is readjusted to a revised 8% CAGR for the next 7-year period. The U.S. Market is Estimated at $823.7 Million, While China is Forecast to Grow at 12.2% CAGR The Vaginitis Therapeutics market in the U.S. is estimated at US$823.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 7.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$709.3 Million by the year 2027. Hormone Segment to Record 8.3% CAGR In the global Hormone segment, USA, Canada, Japan, China and Europe will drive the 8.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$477.8 Million in the year 2020 will reach a projected size of US$800 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 9.8% CAGR through the analysis period. Select Competitors (Total 42 Featured) - Bayer AG Janssen Pharmaceuticals Inc. Lumavita AG Lupin Pharmaceuticals Inc. Merck & Co., Inc. Mission Pharmacal Company Novartis AG Pfizer Inc. Symbiomix Therapeutics LLC Teva Pharmaceutical Industries Ltd Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Vaginitis Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Vaginitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2021 & 2027 Table 4: World Recent Past, Current & Future Analysis for Anti-Bacterial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Anti-Bacterial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Anti-Bacterial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 7: World Recent Past, Current & Future Analysis for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Anti-Fungal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 10: World Recent Past, Current & Future Analysis for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 13: World Recent Past, Current & Future Analysis for Prescription (Rx) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Prescription (Rx) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Prescription (Rx) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 16: World Recent Past, Current & Future Analysis for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Over-the-Counter (OTC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2021 & 2027 Table 19: World Vaginitis Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 III. MARKET ANALYSIS UNITED STATES Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in the United States for 2022 (E) Table 20: USA Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 21: USA Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 22: USA 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 23: USA Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 24: USA Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 25: USA 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 CANADA Table 26: Canada Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 27: Canada Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 28: Canada 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 29: Canada Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 30: Canada Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 31: Canada 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 JAPAN Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in Japan for 2022 (E) Table 32: Japan Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 33: Japan Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 34: Japan 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 35: Japan Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 36: Japan Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 37: Japan 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 CHINA Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in China for 2022 (E) Table 38: China Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 39: China Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 40: China 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 41: China Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 42: China Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 43: China 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 EUROPE Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in Europe for 2022 (E) Table 44: Europe Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 45: Europe Historic Review for Vaginitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 46: Europe 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2021 & 2027 Table 47: Europe Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 48: Europe Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 49: Europe 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 50: Europe Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 51: Europe Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 52: Europe 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 FRANCE Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in France for 2022 (E) Table 53: France Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 54: France Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 55: France 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 56: France Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 57: France Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 58: France 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 GERMANY Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in Germany for 2022 (E) Table 59: Germany Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 60: Germany Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 61: Germany 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 62: Germany Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 63: Germany Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 64: Germany 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 ITALY Table 65: Italy Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 66: Italy Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 67: Italy 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 68: Italy Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 69: Italy Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 70: Italy 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 UNITED KINGDOM Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in the United Kingdom for 2022 (E) Table 71: UK Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 72: UK Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 73: UK 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 74: UK Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 75: UK Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 76: UK 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 SPAIN Table 77: Spain Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 78: Spain Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 79: Spain 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 80: Spain Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 81: Spain Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 82: Spain 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 RUSSIA Table 83: Russia Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 84: Russia Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 85: Russia 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 86: Russia Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 87: Russia Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 88: Russia 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 REST OF EUROPE Table 89: Rest of Europe Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 90: Rest of Europe Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 91: Rest of Europe 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 92: Rest of Europe Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 93: Rest of Europe Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 94: Rest of Europe 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 ASIA-PACIFIC Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in Asia-Pacific for 2022 (E) Table 95: Asia-Pacific Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 96: Asia-Pacific Historic Review for Vaginitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 97: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2021 & 2027 Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 99: Asia-Pacific Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 100: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 102: Asia-Pacific Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 103: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 AUSTRALIA Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in Australia for 2022 (E) Table 104: Australia Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 105: Australia Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 106: Australia 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 107: Australia Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 108: Australia Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 109: Australia 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 INDIA Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in India for 2022 (E) Table 110: India Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 111: India Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 112: India 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 113: India Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 114: India Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 115: India 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 SOUTH KOREA Table 116: South Korea Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 117: South Korea Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 118: South Korea 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 119: South Korea Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 120: South Korea Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 121: South Korea 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 REST OF ASIA-PACIFIC Table 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 123: Rest of Asia-Pacific Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 124: Rest of Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Table 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 126: Rest of Asia-Pacific Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 127: Rest of Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2021 & 2027 LATIN AMERICA Vaginitis Therapeutics Market Presence - Strong/Active/Niche/ Trivial - Key Competitors in Latin America for 2022 (E) Table 128: Latin America Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 129: Latin America Historic Review for Vaginitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 130: Latin America 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2021 & 2027 Table 131: Latin America Recent Past, Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 132: Latin America Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 133: Latin America 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2021 & 2027 Please contact our Customer Support Center to get the complete Table of Contents Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001 SOURCE Reportlinker

注：本文不构成任何投资意见和建议，以上市公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）。 鲁宾制药（Lupin Pharma）是一家跨国制药公司，总部位于印度孟买。由Dr. Desh Bandhu Gupta于1968年成立。研发主体坐落在浦那-马哈拉施特拉邦。Lupin制药提供多种产品，涵盖品牌药物和仿制药、生物药、原料药中间体以及特种化学产品。药物所涉及的疾病领域有：妇科、心血管、糖尿病、哮喘、儿科、中枢神经系统（CNS）、胃肠道（GI）、抗感染（AI）和非甾体抗炎药（NSAIDs）等。公司部分产品在抗结核和头孢菌素领域处于全球领导地位，业务遍及全球100多个国家。目前印度制药巨头Lupin2020年依然正增长;位列全球TOP 10仿制药企。来源：公司财报；  药融圈；由于各国财年不同，仅供参考注：（因Viatris刚重组而成，营收根据21年全年指引） 据公司预计披露，尽管面临着COVID-19疫情的压力，Lupin于2020-2021年（2020/03-2021/03）在全球所有地区依然实现了正增长，尤其是印度的品牌药产品业务，这主要得益于Lupin新产品的推出和品牌建设。更多信息，等待最新一季年报，以下以上一财年年报撰文。 2019-2020年（2019/03-2020/03），Lupin的全球业务在结核病和抗艾滋病毒药物方面取得了里程碑的进展。在仿制药领域，美国市场的价格经历了几年波动之后，现在正走向稳定。在欧洲方面，依那西普生物类似药（Biosimilar）已获得欧洲批准。此外，Lupin的左旋甲状腺素钠占了整体市场比较不错的份额。在战略投资方面，Lupin撤资日本kyowa，资本结构进一步得到了完善。 从总体来说，Lupin的主要市场：印度市场和美国市场的业务增长强劲，业绩占其全球收入的72%。Lupin在美国的仿制药市场上有174种产品，其中有63种在细分市场排名第一，123个产品排名前三，产品平均市场占有率达30%。按处方量计算，公司拥有美国市场第3大仿制药处方。Lupin计划将其营收的10.3%用于药物研发管线和平台的建设，目前有43种产品首次申请上市，其中14个是市场首个申请上市的产品（FTF，First-to-Files），预计在未来将为公司带来丰厚的营收。 美国市场占有率和仿制药市场TRx当时排名 来源：2019-2020年Lupin年报 1主要市场 美国市场 Lupin制药的美国总部位于马里兰州巴尔的摩市，其美国营销部门Lupin 制药公司（LPI）致力于提供该地区医疗保健专业人员和患者信任的特药（Specialty）和仿制药。 在过去五年中，公司在美国研发基础设施和制造生产工厂设施方面进行了战略投资。位于佛罗里达州珊瑚泉的吸入制剂药物研究与发展中心成立于2013年，并于2014年初开始全面运作。2016年收购GAVIS这使得公司能够扩大其在处方管控药物、皮肤科、妇女健康和其他利基市场治疗领域的渠道。 2017年10月，Lupin收购了美国新药公司Symbiomix Therapeutics及其FDA批准的新药Solosec（secnidazole，塞克硝唑颗粒剂）。这是一款治疗细菌性阴道炎的单剂口服疗法（single-dose oral therapy），也是10多年来治疗这一疾病的第一款口服新药。细菌性阴道炎是美国最普遍的女性妇科感染，每年影响2100万年龄在21岁至49岁之间的妇女。对Solosec（secnidazole，塞克硝唑）专营权的收购显著扩展了公司妇女健康专业业务。 2019-2020年在美国的净销售额比去年增长了近3%，贡献了全球销售额的38%，共计8亿美元，主要得益于左旋甲状腺素钠的增长。该产品在美国仿制药市场上依然保持第三的地位，占美国仿制药处方量的6.3%，公司计划来年增加左旋甲状腺素的份额。此外吸入性产品沙丁胺醇正等待美国FDA的审批。 来源：2019-2020年Lupin年报 美国仿制药市场TRx此前排名，供参考，第一位TEVA 来源：2019-2020年Lupin年报 印度市场 印度业务仍然是Lupin的第二大业务部分，营收占其全球收入的34%。2019-2020年印度市场，Lupin品牌仿制药销售额增长了13.6%。目前在印度制药市场（IPM）中排名第六，突破了5亿卢比的里程碑。 复合年增长率一直超过IPM，四年复合年均增长率为11.7%，而IPM为9.4%。重要的是，在过去四年中，Lupin品牌仿制药市场份额从2016年的3.46%提高到2020的3.61%。 Lupin的前十产品在前300个品牌名单中 IPM的市场份额从3.46%提高到了3.61% 来源：2019-2020Lupin年报 2020年心脏病领域、抗糖尿病、呼吸/抗感染、胃肠道用药贡献了公司超过74%的销售额。Lupin继续在抗结核病领域处于印度市场领先地位，在呼吸系统用药保持第二位，在抗糖尿病和心脏病用药领域保持第三位。Lupin在抗糖尿病领域增长显著，为18.4%，而IPM 的增长率为11.8%，市场份额从2019年的7.9% 提高到2020年的8.4%。现在有10 个Lupin 品牌位于IPM 的Top300品牌中。2020年，Lupin成功启动了三个新的部门，专注于泌尿科、皮肤科和儿科呼吸治疗领域。 Lupin的Therapy-wise排名 来源：2019-2020Lupin年报 2Lupin2019-2020年研发方面的主要情况 2020年，Lupin在复杂仿制药制剂的开发和新药研究方面取得了重大进展，2020年Lupin累计申请了430份ANDA文件，被批准的有272份，优先申请的有43份，独家申请的有14份。 原料药API产品和制剂研究 Lupin的仿制药研发布局，主要致力于开发吸入、注射剂、眼科、口腔领域的高准入门槛产品，这些产品和原料药、给药系统、设备设计、临床试验要求有关，需要建设完善的技术平台。据悉，2021年，Lupin将继续投资复杂的仿制药技术平台。 Lupin申请递交了21份ANDA文件，包括口服，可注射，眼科，吸入和皮肤科剂型和2份NDA新药上市申请，已获得美国FDA批准的ANDA文件有14份，有18种产品已在美国上市。在除美国外的其他几个市场提交了11种非专利产品，包括EMEA（欧洲，南非和俄罗斯），亚太地区（日本和澳大利亚），拉美（墨西哥和巴西）和加拿大，获得批准的ANDA文件有10份。 另外，为抗Anti-TB（抗结核）和Antiretroviral（抗逆转录病毒药物）机构的产品提交了2份市场许可批准（MAA）文件，其中，包括一份PEPFAR文件。 Biosimilar研究 2020年Lupin成果显著，在日本完成了与Yoshindo和Nichi-Iko的合作，推出了抗类风湿关节炎的生物类似药Etanercept。 2020年3月，欧洲人用药品委员会(CHMP)通过了一项积极的意见，该意见是基于生物相似性评估，包括临床前和临床研究，证明Enbrel®的生物等效性。 此外，一项针对中重度活动性类风湿性关节炎患者的全球3期临床研究证Nepexto®与Enbrel®的等效性，在有效性、安全性和免疫原性方面具有等价性。 2020年6月，欧盟委员会（EC）授予了Etanercept（品牌为Nepexto®）的上市许可，适用于参考产品的（Enbrel®）的所有适应症。 *主要临床研究的进程 Pegfilgrastim：已获得美国FDA的临床研究批准，正积极展开试验 Ranibizumab：印度正在进行3期临床研究，已启动全球临床试验 Aflibercept:  根据印度政府生物技术部的国家生物制药计划，获得了美国650万美元的拨款 新药研发 目前，Lupin的新药研发团队在肿瘤学、免疫学和代谢障碍等重点治疗领域开发了高度分化和创新的新化学实体。在2019年10月，成功地与Boehringer Ingelheim 合作，推进了临床阶段的MEK抑制剂LNP3794来治疗难以治疗的癌症。（与勃林格殷格翰新兴KRAS抑制剂管线进行联合临床研发，以抗击KRAS突变引发的癌症，该交易鲁宾制药获得2000万美元预付款，并有望获得总额高达7亿美元的潜在阶段性付款以及基于产品销售额的版税） 3财务状况 截止2020年3月31日，Lupin制药综合运营收入为20.64亿美元，同比增长4.8%。国际业务贡献了其收入的63%。 Lupin10年的财务数据总结 来源：2019-2020Lupin年报 2019-2020年美国市场的收入占全球的收入38%，印度市场占全球收入的34%，拉丁美洲和亚太地区都占全球收入的4%，欧洲占比约8%。 截至到2019年3月31日财年结束，Lupin的合并销售额和净利润分别为1636.94亿卢比（23.4亿美元）和94.66亿卢比（1.36亿美元）。 4发展历程 从API到制剂再到新药；从合作/合资/到并购升级，制药企业出海之路。 1968  Lupin开始创立营业  1972  Lupin Laboratories Pvt. Ltd. 成立 1987  Mandideep的Cephalexin工厂和Ankleshwar的7家ADCA工厂正在投产 1988  Lupin人类福利和研究基金会（LHWRF）由Dr. Desh Bandhu Gupta创立 1991在Mandideep公司开始生产Injectable Cephalosporin (Bulk And Dosages)（注射用头孢菌素） 1992  在Maharashtra的Tarapur建立一个叫Lupin Chemicals Ltd.的无菌工厂，用于生产Injectable Cephalosporin 1993  Lupin Laboratories Ltd. 和Lupin Chemicals Ltd. 首次通过IPO筹集资金上市 2000  Mandideep的Cefotaxime Facility 获得了美国食品和药品管理局（FDA）的批准 2001在浦那设立了Lupin最先进的研发中心开始向其在美国的联盟伙伴供应Cephalosporin Bulk ActivesLupin Laboratories Ltd. 和Lupin ChemicalsLtd.合并，并更名为Lupin Ltd.成为唯一一家获得美国FDA批准的有Sterile Cephalosporin 设备的亚洲制药公司美国FDA批准的最先进的Cephalosporin Bulk Active 工厂已在Mandideep投入使用 2003Aurangabad的配方工厂获得世卫组织批准的最先进的称号成功在公司范围内实施SAPERP，以统一所有业务职能和流程在内联网中引入协作消息传递和工作流解决方案Mandideep的Oral Cephalosporin工厂获得美国FDA批准Lupin Pharmaceuticals Inc.USA成立，从事贸易、营销和发展活动 2011在Pithampur的新型口服固体剂量设施开始商业化生产在日本收购I'rom Pharmaceuticals与Medicis签订联合开发协议取得Goanna®品牌的全球版权 2014与日本Yoshindo Inc.签署战略合资协议收购墨西哥专业眼科公司Laboratorios Grin S.A. De C.V.并以此进入拉丁美洲市场收购NanomiB.V.，进入复杂的注射剂领域 2015Florida珊瑚泉吸入研究中心成立收购德国Temmler Pharma GmbH＆Co.的特殊产品组合在巴西收购Medquimica Industria Farmaceutica S.A.收购南非制药公司 2018收购新泽西州的Symbiomix Therapeutics，LLC推出Softovac®进入OTC领域在Sikkim开设新工厂 2019  从Kyowa Pharmaceutical Industry Co.撤资 参考： NMPA/CDE；药融云数据 www.pharnexcloud.com； FDA/EMA； 相关公司公开披露； 鲁宾制药官网：https://www.lupin.com/； Lupin2019-2020年报； https://www.drugs.com/solosec.html； Lupin Presents Phase 3 Data for Solosec (secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis； https://www.prnasia.com/story/256885-1.shtml；等等。 【关于药融圈】药融圈围绕我国生物医药产业链，针对生物医药大数据、技术和资本投资、药融园(产业园)等开展系列系统性工作，促进我国生物医药产业健康发展，完善产业链，共同面对全球合作和竞争。 点分享 点点赞点在看

New York, March 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Vaginitis Therapeutics Industry" - In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations. Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments. Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience. Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics. Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations. Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives. Abstract: - Global Vaginitis Therapeutics Market to Reach $4.4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Vaginitis Therapeutics estimated at US$2.7 Billion in the year 2020, is projected to reach a revised size of US$4.4 Billion by 2027, growing at a CAGR of 7.1% over the analysis period 2020-2027. Anti-Bacterial, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$1.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Anti-Fungal segment is readjusted to a revised 7.2% CAGR for the next 7-year period. - The U.S. Market is Estimated at $735 Million, While China is Forecast to Grow at 10.8% CAGR - The Vaginitis Therapeutics market in the U.S. is estimated at US$735 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$965.9 Million by the year 2027 trailing a CAGR of 10.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.9% and 6.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR. - Hormone Segment to Record 7.4% CAGR - In the global Hormone segment, USA, Canada, Japan, China and Europe will drive the 6.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$428.8 Million in the year 2020 will reach a projected size of US$680.5 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$604 Million by the year 2027, while Latin America will expand at a 8.8% CAGR through the analysis period. Select Competitors (Total 42 Featured) - Bayer AG Janssen Pharmaceuticals Inc. Lumavita AG Lupin Pharmaceuticals Inc. Merck & Co., Inc. Mission Pharmacal Company Novartis AG Pfizer Inc. Symbiomix Therapeutics LLC Teva Pharmaceutical Industries Ltd Read the full report: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Vaginitis Therapeutics Competitor Market Share Scenario Worldwide (in %): 2020E Global Competitor Market Shares by Segment 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 2: World Historic Review for Vaginitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 3: World 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027 Table 4: World Current & Future Analysis for Anti-Bacterial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 5: World Historic Review for Anti-Bacterial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 6: World 15-Year Perspective for Anti-Bacterial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 7: World Current & Future Analysis for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 8: World Historic Review for Anti-Fungal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 9: World 15-Year Perspective for Anti-Fungal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 10: World Current & Future Analysis for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 11: World Historic Review for Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 12: World 15-Year Perspective for Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 13: World Current & Future Analysis for Prescription (Rx) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 14: World Historic Review for Prescription (Rx) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 15: World 15-Year Perspective for Prescription (Rx) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 Table 16: World Current & Future Analysis for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 17: World Historic Review for Over-the-Counter (OTC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 18: World 15-Year Perspective for Over-the-Counter (OTC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027 III. MARKET ANALYSIS UNITED STATES Market Facts & Figures Market Analytics Table 19: USA Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 20: USA Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 21: USA 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 22: USA Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 23: USA Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 24: USA 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 CANADA Table 25: Canada Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 26: Canada Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 27: Canada 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 28: Canada Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 29: Canada Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 30: Canada 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 JAPAN Table 31: Japan Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 32: Japan Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 33: Japan 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 34: Japan Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 35: Japan Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 36: Japan 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 CHINA Table 37: China Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 38: China Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 39: China 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 40: China Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 41: China Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 42: China 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 EUROPE Market Facts & Figures Market Analytics Table 43: Europe Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 44: Europe Historic Review for Vaginitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 45: Europe 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027 Table 46: Europe Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 47: Europe Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 48: Europe 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 49: Europe Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 50: Europe Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 51: Europe 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 FRANCE Table 52: France Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 53: France Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 54: France 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 55: France Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 56: France Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 57: France 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 GERMANY Table 58: Germany Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 59: Germany Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 60: Germany 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 61: Germany Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 62: Germany Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 63: Germany 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 ITALY Table 64: Italy Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 65: Italy Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 66: Italy 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 67: Italy Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 68: Italy Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 69: Italy 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 UNITED KINGDOM Table 70: UK Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 71: UK Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 72: UK 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 73: UK Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 74: UK Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 75: UK 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 SPAIN Table 76: Spain Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 77: Spain Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 78: Spain 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 79: Spain Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 80: Spain Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 81: Spain 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 RUSSIA Table 82: Russia Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 83: Russia Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 84: Russia 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 85: Russia Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 86: Russia Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 87: Russia 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 REST OF EUROPE Table 88: Rest of Europe Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 89: Rest of Europe Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 90: Rest of Europe 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 91: Rest of Europe Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 92: Rest of Europe Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 93: Rest of Europe 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 ASIA-PACIFIC Table 94: Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 95: Asia-Pacific Historic Review for Vaginitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 96: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027 Table 97: Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 98: Asia-Pacific Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 99: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 100: Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 101: Asia-Pacific Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 102: Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 AUSTRALIA Table 103: Australia Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 104: Australia Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 105: Australia 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 106: Australia Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 107: Australia Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 108: Australia 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 INDIA Table 109: India Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 110: India Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 111: India 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 112: India Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 113: India Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 114: India 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 SOUTH KOREA Table 115: South Korea Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 116: South Korea Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 117: South Korea 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 118: South Korea Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 119: South Korea Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 120: South Korea 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 REST OF ASIA-PACIFIC Table 121: Rest of Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 122: Rest of Asia-Pacific Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 123: Rest of Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 124: Rest of Asia-Pacific Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 125: Rest of Asia-Pacific Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 126: Rest of Asia-Pacific 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 LATIN AMERICA Table 127: Latin America Current & Future Analysis for Vaginitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR Table 128: Latin America Historic Review for Vaginitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 129: Latin America 15-Year Perspective for Vaginitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027 Table 130: Latin America Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 131: Latin America Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 132: Latin America 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 133: Latin America Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 134: Latin America Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 135: Latin America 15-Year Perspective for Vaginitis Therapeutics by Type - Percentage Breakdown of Value Sales for Prescription (Rx) and Over-the-Counter (OTC) for the Years 2012, 2020 & 2027 ARGENTINA Table 136: Argentina Current & Future Analysis for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 137: Argentina Historic Review for Vaginitis Therapeutics by Product - Anti-Bacterial, Anti-Fungal and Hormone Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 138: Argentina 15-Year Perspective for Vaginitis Therapeutics by Product - Percentage Breakdown of Value Sales for Anti-Bacterial, Anti-Fungal and Hormone for the Years 2012, 2020 & 2027 Table 139: Argentina Current & Future Analysis for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR Table 140: Argentina Historic Review for Vaginitis Therapeutics by Type - Prescription (Rx) and Over-the-Counter (OTC) Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR Table 141: Argentina 15-Year Perspective for Vaginitis Please contact our Customer Support Center to get the complete Table of Contents Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________